Incheon plant secures standalone commercial CMO deal ahead of official completion; contract covers full drug substance-to-finished product supply
Client identity and contract value undisclosed under confidentiality terms; revenue secured to coincide with full operation next year
Win comes a day after Shin Yu-yeol's promotion to president, accelerating dual-site synergy between Syracuse and Songdo
Lotte Biologics has secured its first commercial production contract for Factory 1 at its Songdo Bio Campus in Incheon, ahead of the plant's official completion ceremony.
The win came just one day after Shin Yu-yeol — the third-generation owner-family executive who has led Lotte Group's biotech push — was promoted to president, marking what industry observers are calling the true opening of the "Songdo era."
Lotte Biologics announced Tuesday it had signed a contract manufacturing organization (CMO) agreement with a global pharmaceutical company for biopharmaceutical production. The identity of the client and the specific contract value and volume were not disclosed under a mutual confidentiality clause, though the company described it as a large-scale commercial production order.
The significance of the deal lies in its being the first commercial production order secured exclusively for Factory 1 at the Songdo Bio Campus. Lotte Biologics had previously signed a 10-year drug substance CMO agreement with European biosimilar specialist Alvotech at CPHI Worldwide 2026 in Milan last month.
That earlier deal was structured as a linked model — initial production and validation at the Syracuse, New York facility, followed by a technology transfer to Songdo Factory 1 at a later stage. The latest contract, by contrast, is the first case in which a global client has been brought on board on the premise of direct production at Songdo Factory 1, even before the plant has been formally completed.
The result is a vindication of a "pre-order strategy" that breaks with standard contract development and manufacturing organization (CDMO) industry practice — which calls for client due diligence, quality verification and order solicitation to proceed sequentially only after a facility is completed — by locking in commercial volume during the design and construction phase. With the hardware milestone of factory completion and the software achievement of a commercial order now aligned, Songdo Factory 1 is positioned to begin full commercial production next year while eliminating early vacancy risk and securing a stable revenue base from the outset.
Under the agreement, Lotte Biologics will provide a one-stop service covering the entire production process for the client's key drugs — from clinical drug substance manufacturing through to finished drug product.
Factory 1, where the contracted volume will be produced, is a state-of-the-art smart plant with a total capacity of 120,000 liters, equipped with eight 15,000-liter stainless steel bioreactors. The facility received its building use approval just two years after breaking ground. The company has also moved its Good Manufacturing Practice (GMP) readiness timeline forward by more than six months — from the originally planned April 2027 to this month — in response to requests from global clients for earlier operation, with the official completion ceremony now imminent.
The plant incorporates advanced infrastructure: a vertically integrated structure in which culture media is prepared on the top floor and fed down to lower production lines, an unmanned robotic logistics warehouse with 6,030 storage slots, and a real-time monitoring system anchored by a central control room.
Industry observers credit the win to what they call "Shin Yu-yeol leadership" and the quality credentials established at the Syracuse facility. Shin, who serves as co-CEO of Lotte Biologics, was promoted to president in Lotte Group's 2027 regular executive reshuffle announced Monday and will also take charge of the group's management strategy division — a role that reflects his hands-on stewardship of the biotech business.
Shin has attended the JP Morgan Healthcare Conference in San Francisco for three consecutive years since 2024 and has personally led partnering meetings with prospective clients at major global industry events including Bio USA in Boston, CPHI Worldwide in Milan and Bio Japan in Yokohama.
Reinforcing that outreach is the quality track record built at the Syracuse Bio Campus — more than 62 regulatory approvals from global agencies and a zero-observation outcome in a recent unannounced FDA inspection — which has helped build global client confidence in the newly constructed Songdo facility.
The company's dual-site strategy — linking the Syracuse campus, which excels in clinical-batch production and antibody-drug conjugate one-stop services, with the Songdo campus as a 120,000-liter commercial production hub — has proven its competitive edge amid the global supply chain realignment driven by biosecurity legislation and related regulatory shifts.
The consolidation last August of roughly 800 headquarters and research staff from the Jamsil head office into the new Songdo Bio Campus building, completing a "one-team" structure, also laid the groundwork for the company's rapid order-response capability.
"This contract demonstrates that Lotte Biologics is establishing itself as a core supply chain partner for global clients, not merely a new entrant in the CDMO space," said Lotte Biologics co-CEO Park James. "Building on our accumulated quality credentials and stable supply capabilities, we will actively support our clients' successful commercialization of new drugs."
silverpaper@heraldcorp.com
